|
SOCIODEMOGRAPHIC
|
|
Age (years)
|
12.4 (4.7)
|
11.8 (4.8)
|
12.9 (4.6)
|
|
Female
|
1675/2356 (71%)
|
723/1024 (71%)
|
929/1304 (71%)
|
|
Race (White)
|
1885/2207 (85%)
|
824/970 (85%)
|
1045/1216 (86%)
|
|
Insurance Status (Private)
|
1536/1769 (87%)
|
713/812 (88%)
|
814/946 (86%)
|
|
CLINICAL CHARACTERISTICS
|
|
Disease Duration (months)
|
68.1 (49.1)
|
69.0 (48.4)
|
67.2 (49.4)
|
|
ILAR Subtype
|
|
Polyarticular, RF (-)
|
790 (29%)
|
350 (28%)
|
420 (29%)
|
|
Oligoarticular, persistent
|
768 (28%)
|
417 (33%)
|
330 (23%)
|
|
Enthesitis related arthritis
|
332 (12%)
|
115 (9%)
|
207 (14%)
|
|
Oligoarticular, extended
|
286 (10%)
|
138 (11%)
|
136 (10%)
|
|
Psoriatic arthritis
|
184 (7%)
|
61 (5%)
|
121 (8%)
|
|
Systemic arthritis
|
174 (6%)
|
87 (7%)
|
83 (6%)
|
|
Polyarticular, RF (+)
|
157 (6%)
|
55 (4%)
|
100 (7%)
|
|
Undifferentiated
|
54 (2%)
|
25 (2%)
|
27 (2%)
|
|
ANA Positive
|
1339 (49%)
|
611 (49%)
|
691 (49%)
|
|
DISEASE ACTIVITY MEASURES
|
|
Active Uveitis
|
133/2393 (6%)
|
0
|
129/1286 (10%)
|
|
Systemic Features
|
21 (<1%)
|
0
|
21 (1%)
|
|
Morning Stiffness > 15 min
|
1934/2389 (81%)
|
0
|
452/1303 (35%)
|
|
Elevated ESR / CRP
|
204 (7%) / 139 (5%)
|
0
|
204 (14%) / 139 (10%)
|
|
Active Joint Count
|
0.9 (2.0)
|
0
|
1.8 (2.5)
|
|
MD Global Assessment
|
1.0 (1.4)
|
0.03 (0.1)
|
1.8 (1.5)
|
|
PATIENT-REPORTED MEASURES
|
|
Patient Global Assessment (0-10)
|
1.7 (2.3)
|
0.74 (1.5)
|
2.6 (2.5)
|
|
Pain Score (0-10)
|
2 (2.5)
|
0.8 (1.5)
|
2.9 (2.8)
|
|
CHAQ
|
0.24 (0.44)
|
0.11 (0.26)
|
0.36 (0.52)
|
|
MEDICATIONS
|
|
Non-biologic DMARDs
|
1059 (38%)
|
399 (32%)
|
640 (45%)
|
|
Methotrexate
|
914 (86%)
|
350 (88%)
|
549 (86%)
|
|
Leflunomide
|
68 (6%)
|
24 (6%)
|
43 (7%)
|
|
Sulfasalazine
|
51 (5%)
|
16 (4%)
|
34 (5%)
|
|
Hydroxychloroquine
|
43 (4%)
|
7 (2%)
|
34 (5%)
|
|
Other
|
14 (1%)
|
5 (1%)
|
10 (2%)
|
|
More than one
|
33 (3%)
|
3 (<1%)
|
30 (5%)
|
|
Biologic DMARDs
|
1101 (40%)
|
434 (35%)
|
684 (48%)
|
|
All Anti-TNF
|
863 (31%)
|
350 (28%)
|
498 (35%)
|
|
Etanercept
|
420 (38%)
|
191 (44%)
|
223 (33%)
|
|
Adalimumab
|
331 (30%)
|
125 (29%)
|
202 (30%)
|
|
Infliximab
|
105 (10%)
|
32 (7%)
|
68 (10%)
|
|
Certolizumab
|
9 (<1%)
|
5 (1%)
|
4 (<1%)
|
|
Golimumab
|
8 (<1%)
|
3 (<1%)
|
5 (<1%)
|
|
Tocilizumab
|
97 (9%)
|
32 (7%)
|
64 (9%)
|
|
Abatacept
|
80 (7%)
|
20 (5%)
|
60 (9%)
|
|
Anakinra
|
23 (2%)
|
13 (3%)
|
9 (1%)
|
|
Canakinumab
|
21 (2%)
|
12 (3%)
|
8 (1%)
|
|
Rituximab
|
6 (<1%)
|
1 (<1%)
|
4 (<1%)
|
|
Tofacitinib
|
4 (<1%)
|
0
|
4 (<1%)
|
|
Other
|
2 (<1%)
|
2 (<1%)
|
0
|
|
More than one
|
5 (<1%)
|
2 (<1%)
|
3 (<1%)
|
|
NSAIDs
|
|
Daily
|
770 (28%)
|
204 (16%)
|
551 (29%)
|
|
Intermittent
|
345 (13%)
|
150 (12%)
|
195 (14%)
|
|
Glucocorticoids
|
|
Intra-articular
|
201 (7%)
|
46 (4%)
|
147 (10%)
|
|
Systemic
|
84 (3%)
|
17 (1%)
|
63 (4%)
|
|
Ophthalmic
|
119 (4%)
|
19 (2%)
|
94 (7%)
|
